GRAIL (NASDAQ:GRAL) Shares Gap Up – What’s Next?

Shares of GRAIL, Inc. (NASDAQ:GRAL) gapped up before the market opened on Monday . The stock had previously closed at $80.77, but opened at $93.74. GRAIL shares last traded at $102.00, with a volume of 601,651 shares traded.

GRAIL News Roundup

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Favorable FDA assessment supports Galleri prospects. FDA staff reportedly identified no major concerns with the test and highlighted its accuracy and low false-positive rate. The briefing materials have strengthened expectations that Galleri could advance through the regulatory process. Reuters article
• Positive Sentiment: Analyst raises price target and rating. Robert W. Baird lifted its target for GRAIL from $96 to $118 and assigned an “outperform” rating, implying additional upside based on the stock’s referenced price. The upgrade reflects improved confidence surrounding Galleri’s regulatory outlook. TickerReport article
• Positive Sentiment: Investor focus remains on the FDA review. Multiple reports attributed GRAIL’s recent rally to the release of FDA documents before the advisory committee meeting, suggesting the market is pricing in a higher probability of a positive outcome for Galleri. Benzinga article
• Neutral Sentiment: Regulatory uncertainty remains. The FDA advisory committee still must evaluate Galleri, and favorable staff comments do not ensure approval. The panel’s recommendation and subsequent FDA decision will likely remain major near-term catalysts for GRAL.
• Negative Sentiment: Fundamental losses remain a risk. GRAIL continues to operate at a substantial loss, with analysts forecasting negative full-year earnings. A disappointing FDA outcome or concerns about commercialization could therefore trigger volatility after the recent rally.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GRAL. Royal Bank Of Canada started coverage on GRAIL in a report on Thursday, September 17th. They issued a “sector perform” rating and a $84.00 price objective on the stock. The Goldman Sachs Group assumed coverage on shares of GRAIL in a research report on Friday, June 5th. They set a “neutral” rating and a $60.00 price target on the stock. UBS Group set a $84.00 target price on shares of GRAIL in a research report on Thursday, September 17th. Robert W. Baird upped their price target on GRAIL from $96.00 to $118.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, TD Cowen reissued a “buy” rating on shares of GRAIL in a research report on Wednesday, July 15th. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, GRAIL has an average rating of “Hold” and a consensus price target of $75.10.

GRAIL Price Performance

The firm has a 50 day moving average of $75.56 and a two-hundred day moving average of $64.31. The stock has a market cap of $4.85 billion, a PE ratio of -11.13 and a beta of 3.25.

GRAIL (NASDAQ:GRAL) last posted its earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.10. The firm had revenue of $44.69 million for the quarter, compared to the consensus estimate of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. As a group, equities analysts anticipate that GRAIL, Inc. will post -10.41 EPS for the current fiscal year.

Insider Activity at GRAIL

In related news, CEO Joshua J. Ofman sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $85.02, for a total transaction of $425,100.00. Following the transaction, the chief executive officer owned 397,271 shares of the company’s stock, valued at $33,775,980.42. This trade represents a 1.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Freidin sold 7,900 shares of GRAIL stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $85.01, for a total value of $671,579.00. Following the completion of the transaction, the chief financial officer owned 253,083 shares in the company, valued at $21,514,585.83. This trade represents a 3.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.83% of the stock is currently owned by corporate insiders.

Institutional Trading of GRAIL

Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp increased its holdings in GRAIL by 26.1% in the second quarter. State Street Corp now owns 2,385,514 shares of the company’s stock valued at $162,859,000 after buying an additional 493,621 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in GRAIL by 26.3% during the second quarter. The Manufacturers Life Insurance Company now owns 21,597 shares of the company’s stock worth $1,474,000 after buying an additional 4,498 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in GRAIL in the 2nd quarter valued at about $82,000. Arizona State Retirement System raised its position in shares of GRAIL by 8.6% in the second quarter. Arizona State Retirement System now owns 10,470 shares of the company’s stock valued at $715,000 after buying an additional 833 shares during the last quarter. Finally, Nykredit A S acquired a new position in GRAIL in the 2nd quarter valued at $96,000.

About GRAIL

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021.